Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mytrex Health TechnologiesROCO:4431 +2.06%64 Gross Margin % is 12.15% as of Dec. 2025, which is 23% below its 10-year median of 15.78. GuruFocus rates ROCO:4431 with a GF Score™ of 64/100 and a GF Value™ of NT$37.17 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 2,996 Industrial Products companies, Mytrex Health Technologies ranks worse than 85.45% on this metric.
Mytrex Health Technologies (ROCO:4431) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Mytrex Health Technologies had a gross margin of 12.15% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Mytrex Health Technologies Gross Margin % Related Terms
Mytrex Health Technologies Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4431 vs GEV, ETN, PH: Gross Margin % Comparison
For the Specialty Industrial Machinery subindustry, Mytrex Health Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mytrex Health Technologies Gross Margin % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Mytrex Health Technologies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Mytrex Health Technologies's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Mytrex Health Technologies (ROCO:4431) has a Gross Margin % of 12.15% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Mytrex Health Technologies and its competitors. This is 23% below median its historical median of 15.78. Over the past decade, Mytrex Health Technologies' Gross Margin % has ranged from 12.47 to 61.40. According to the industry distribution chart, Mytrex Health Technologies ranks #2560 out of 2996 companies in the Industrial Products industry, placing it in the top 85.4%.
Is Mytrex Health Technologies' Gross Margin % too high?
Mytrex Health Technologies' current Gross Margin % of 12.15% is 23% below median its 10-year median of 15.78. Over the past 10 years, this metric has ranged from a low of 12.47 to a high of 61.40. The Industrial Products industry median Gross Margin % is 26.80. Mytrex Health Technologies' value of 12.15% is 54.7% below this industry median. Based on the distribution chart, Mytrex Health Technologies ranks #2560 out of 2996 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Mytrex Health Technologies has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mytrex Health Technologies' Gross Margin % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Mytrex Health Technologies ranks #2560 out of 2996 companies for Gross Margin %. This places Mytrex Health Technologies in the lower half of its industry. The industry median Gross Margin % is 26.80. Mytrex Health Technologies' value of 12.15% is 54.7% below this benchmark. Historically, Mytrex Health Technologies' own Gross Margin % has ranged from 12.47 to 61.40 over the past decade. While the company's 10-year median is 15.78 vs. the industry median of 26.80, Mytrex Health Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for an Industrial Products company?
The median Gross Margin % among Industrial Products companies is 26.80, based on 2,996 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mytrex Health Technologies's current Gross Margin % of 12.15% is 54.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Mytrex Health Technologies and its competitors. For the Industrial Products industry, the median Gross Margin % is 26.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mytrex Health Technologies's current Gross Margin % is 12.15%, which is 23% below median its own 10-year median of 15.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mytrex Health Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mytrex Health Technologies (ROCO:4431) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$37.17, compared to a current price of NT$17.35 — trading 53.3% below its estimated fair value. The current Gross Margin % is 12.15%, which is 23% below median its 10-year median of 15.78 and 54.7% below the Industrial Products industry median of 26.80. Mytrex Health Technologies' overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Mytrex Health Technologies (ROCO:4431), the current Gross Margin % is 12.15% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mytrex Health Technologies (ROCO:4431) Overvalued in 2026?
Based on GuruFocus' analysis, Mytrex Health Technologies stock appears to be undervalued.
The current stock price of NT$17.35 is trading 53.3% below its estimated GF Value™ of NT$37.17.
GuruFocus considers Mytrex Health Technologies to be Significantly Undervalued.
Key valuation signals for ROCO:4431:
Gross Margin %: 12.15% (23% below median its 10-year median of 15.78)
GF Value™: NT$37.17 vs. price of NT$17.35 (53.3% below fair value)
Industry Position: 54.7% below the Industrial Products median (#2560 of 2996)
No single metric tells the full story. See the ROCO:4431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mytrex Health Technologies Inc is a Taiwan-based company engaged in the manufacturing of non-woven materials and special medical supplies. It is engaged in the development and production of melt-blown products for the protection of the environment and human health. The company offers products ranging from medical to industrial filtration materials such as various types of filtration media, lab coats or outfits, cabin filtration, vacuum cleaner filter bags, and special medical supplies. Its product categories include meltdown, mammoth bedding, and specialized medical supplies like balloon catheters and coronary stents.
64GF Score
Get the complete analysis for ROCO:4431
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4431 has been successfully added to your 
